Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
about
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesMacrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell LinesPlasmonic nanobubbles rapidly detect and destroy drug-resistant tumorsMicrobubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo.Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing miceTreatment of locally advanced head and neck cancer: historical and critical review.The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case SeriesEGFR expression in advanced head and neck cutaneous squamous cell carcinoma.A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.Control of oncogenesis and cancer therapy resistance.Novel targeted agents in the treatment of lung cancer.Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway.A review of erlotinib and its clinical use.Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFRPrognostic significance of nm23-H1 expression in oral squamous cell carcinomaQuantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imagingNew targets for non-small-cell lung cancer therapy.Anticipatory activation of the unfolded protein response by epidermal growth factor is required for immediate early gene expression and cell proliferation.Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).Predictive and prognostic markers in colorectal cancer.Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).Challenges in monoclonal antibody-based therapies.Targeting the epidermal growth factor receptor in solid tumor malignancies.Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.Traditional Chinese Medicine: Salvia miltiorrhiza Enhances Survival Rate of Autologous Adipose Tissue Transplantation in Rabbit Model.Epidermal growth factor receptor inhibition by anti-CD147 therapy in cutaneous squamous cell carcinoma.CKAP4 inhibited growth and metastasis of hepatocellular carcinoma through regulating EGFR signaling.Cloning and expression of the functional human anti-vascular endothelial growth factor (VEGF) using the pcDNA3.1 vector and the human chronic myelogenous leukemia cell line K562.Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors.Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma.Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.Porcine epidemic diarrhea virus-induced epidermal growth factor receptor activation impairs the antiviral activity of type I interferon.Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry.
P2860
Q27690917-4CC39795-0152-41E0-B330-87DDA0DACA12Q30367534-854EF52B-F65F-438A-94B0-D32326DB0462Q30461227-2030F285-28DB-409C-BA12-8F25355922B3Q30464657-B3B902E8-F392-4029-84D5-F3B1A325BC0AQ30480832-BB6DF4D3-CE5A-4441-BD20-8A937378BCA4Q33856506-7220B06C-505B-4D5E-B481-B2A098D1F7FCQ34157174-B4A692C0-596F-4479-BA5A-B0666AC842CBQ35104586-C562CB2B-4854-4F41-AE3B-3882E63BBF5DQ35353893-33D386C5-62E1-4DDD-A0C0-0F244EF6BB11Q35597532-47A235DF-AB42-416C-96FF-D2FEB2078776Q35647847-CEB477A6-6203-4B4C-9139-383BA9B4FBB5Q35647850-FD4131A0-8895-4026-83DE-E354E468E4F0Q35790783-2417D07D-D1F7-4A82-9DBA-8E21BC19B928Q35810510-8166D807-EB4A-4C23-B1B0-016DE50E4179Q36088163-E74FCE77-4D4A-4333-B816-884F1AF9DEABQ36146089-BBC24FFD-CB14-44C9-9568-18080622F64DQ36376408-9D1A4F70-3F5C-4C42-8D98-F3592B556136Q36616502-138C9393-F760-48D4-8278-118809457E6CQ36694199-8E639B60-0A0D-48B1-B874-C4A9A04C3A81Q36813117-5E96A102-13FB-4ABE-B366-45B722E361EDQ36974703-FC819B10-99D1-4B5F-97A7-C6A40CFE97B4Q37033459-6E60B678-7D74-48C5-8AF1-3CF03CFABEA2Q37052752-19FEC5EB-EBE1-4AB4-B7C5-2AE58E8AD261Q37073444-76EF505F-0A9E-45D5-ACD3-BFEEAF15AB7EQ37310298-50D9E1FE-6189-4749-B666-F73B76CC5216Q37398725-94B7A9F7-E7CB-4117-94A1-202293470074Q37990044-2DB611B6-6FBC-4CAB-B7A1-DBDCF4017639Q37992086-2BC54389-B397-494D-89B2-EB7106BCE5B1Q38536377-AA7B06CB-35CC-4239-A4BD-AF7FCCB1D854Q38601777-C13269A0-2A95-43EC-B141-94EDBB63A8DFQ38951777-6057569C-7860-4ADD-9DCB-627C77929422Q38993980-1C45F325-3DB1-44AA-B1EA-A6F5A6B1EA0EQ39036591-CDC7D410-AED6-4762-9C97-DF2FDFE6B624Q39269129-358E7151-E1F7-4790-9004-336830A2C1F2Q39512157-9565FD3C-06E9-4844-BB82-A05F3977EED1Q41289945-8F3549EB-414E-4F23-82CB-7BEA6B58C7D5Q42677389-6D397A0E-1419-4C5C-91DF-4CDF34EAE600Q44185661-88040DEA-722D-411E-A238-40A3E19ED0C3Q47547475-B339639F-CF80-4485-BE25-D2F614874F59Q53644641-1C6AF8B0-D0AA-4C08-B1E9-62B05476CF86
P2860
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Epidermal growth factor recept ...... ung and head and neck cancers.
@ast
Epidermal growth factor recept ...... ung and head and neck cancers.
@en
Epidermal growth factor recept ...... ung and head and neck cancers.
@nl
type
label
Epidermal growth factor recept ...... ung and head and neck cancers.
@ast
Epidermal growth factor recept ...... ung and head and neck cancers.
@en
Epidermal growth factor recept ...... ung and head and neck cancers.
@nl
prefLabel
Epidermal growth factor recept ...... ung and head and neck cancers.
@ast
Epidermal growth factor recept ...... ung and head and neck cancers.
@en
Epidermal growth factor recept ...... ung and head and neck cancers.
@nl
P356
P1433
P1476
Epidermal growth factor recept ...... ung and head and neck cancers.
@en
P2093
Corey J Langer
P356
10.1053/SONC.2002.31525
P433
P577
2002-02-01T00:00:00Z